This inventor holds 3 USPTO granted patents and 15 published patent applications, plus 1 CIPO patent and 4 EPO patents. Top assignee: Momenta Pharmaceuticals, Inc.. Active years: 2013-2026.
Company Filing History:
Years Active: 2013-2026
Title: Hetal Sarvaiya: Innovator in Glycoprotein Production
Introduction
Hetal Sarvaiya is a notable inventor based in Quincy, MA (US). He has made significant contributions to the field of glycoprotein products, particularly through his innovative methods involving Chinese hamster ovary (CHO) cells. With a total of 3 patents, Sarvaiya's work is paving the way for advancements in therapeutic fusion proteins.
Latest Patents
Sarvaiya's latest patents include groundbreaking methods for producing recombinant therapeutic fusion proteins. One patent focuses on the use of galactose-alpha-1, 3-galactose-containing N-glycans in glycoprotein products derived from CHO cells. This method involves culturing CHO cells under specific conditions to express recombinant therapeutic fusion proteins, treating the glycans with exoglycosidases, and measuring the presence of terminal galactose-alpha-1-3-galactose residues using nuclear magnetic resonance (NMR). Another patent emphasizes the evaluation of CHO cells in the production of these glycoprotein products.
Career Highlights
Hetal Sarvaiya is currently employed at Momenta Pharmaceuticals, Inc., where he continues to innovate in the field of biopharmaceuticals. His work is instrumental in enhancing the efficacy and safety of therapeutic proteins, which are crucial for various medical treatments.
Collaborations
Throughout his career, Sarvaiya has collaborated with talented professionals, including Carlos J Bosques and Jennifer Murphy. These collaborations have fostered a productive environment for research and development in glycoprotein technologies.
Conclusion
Hetal Sarvaiya's contributions to the field of glycoprotein production through his innovative patents and collaborations highlight his role as a key inventor in the biopharmaceutical industry. His work continues to influence advancements in therapeutic applications.